News headlines about PDL BioPharma (NASDAQ:PDLI) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PDL BioPharma earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 48.2223275737303 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

A number of analysts have recently weighed in on PDLI shares. BidaskClub cut shares of PDL BioPharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 8th. TheStreet cut shares of PDL BioPharma from a “c-” rating to a “d+” rating in a report on Friday, August 17th. Cowen restated a “hold” rating and issued a $2.50 price target on shares of PDL BioPharma in a report on Thursday, June 14th. Zacks Investment Research upgraded shares of PDL BioPharma from a “sell” rating to a “hold” rating in a report on Tuesday, June 19th. Finally, ValuEngine cut shares of PDL BioPharma from a “buy” rating to a “hold” rating in a report on Thursday, August 23rd. Two research analysts have rated the stock with a sell rating and two have given a hold rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $3.00.

Shares of NASDAQ:PDLI traded up $0.09 during trading on Friday, reaching $2.44. The stock had a trading volume of 100,460 shares, compared to its average volume of 1,020,913. PDL BioPharma has a one year low of $2.27 and a one year high of $3.55. The stock has a market capitalization of $338.78 million, a P/E ratio of 3.87 and a beta of 0.31. The company has a debt-to-equity ratio of 0.17, a quick ratio of 10.80 and a current ratio of 11.13.

PDL BioPharma (NASDAQ:PDLI) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.04. PDL BioPharma had a negative net margin of 31.33% and a positive return on equity of 8.92%. The business had revenue of $46.58 million for the quarter. research analysts forecast that PDL BioPharma will post -0.6 EPS for the current year.

PDL BioPharma Company Profile

PDL BioPharma, Inc acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices.

Read More: How is a Moving Average Calculated?

Insider Buying and Selling by Quarter for PDL BioPharma (NASDAQ:PDLI)

Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with's FREE daily email newsletter.